The Food and Drug Administration, Office of Prescription Drug Promotion, has issued two new draft guides that illustrate the administration’s current approach to the use of the Internet and social media to promote drugs, according to Ginny Boland, assistant vice president of strategic communications at McGuire Woods, in a post on the FDA Life blog.
The “Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Presecription Drugs and Medical Devices” guide speaks to situations when pharmaceutical companies, drug makers and medical device manufacturers respond to a third-party’s communication that contains drug misinformation. The response should be, among other things, “non-promotional, accurate, relevant and responsive to the misinformation.” It also must be posted alongside the misinformation in the same forum.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]